Compare SAP SE (SAP) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SAP SE vs Tango Therapeutics Inc. — how do they compare? SAP SE trades at $222.88 (market cap $254.11B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: SAP SE is far larger — about 67.8× Tango Therapeutics Inc.'s market cap, and SAP SE pays a 1.33% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold SAP SE for 118 Days and Tango Therapeutics Inc. for 0 Days on average.
| SAP | TNGX | |
|---|---|---|
Market Cap | $254.11B | $3.75B |
Volume | 2,139,071 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $280.46 | $32.90 |
52-Week Low | $146.38 | $7.50 |
Typical Hold Time | 118 Days | 0 Days |
Enterprise Value | $252.86B | $2.77B |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SAP trades at $220.49, up 1.21% today, with a bullish technical outlook supported by moving averages and a consensus price target of $253.60. The company reported strong revenue growth to $36.80B in 2025 and a net income margin of 20.41%, though Q2 2026 EPS missed expectations. Recent news highlights AI-driven cloud revenue growth and partnerships, while cash flow trends show variability with a net outflow of $1.39B in 2025.
The stock presents upside potential based on analyst targets and robust fundamentals, but risks include competitive pressures in enterprise software and execution challenges in AI integration. Investors should weigh solid profitability against valuation multiples like a P/E of 29.48, which may limit near-term gains if growth moderates.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
